Orbis Research has announced the addition of the Global Abilify Market by company, by country, and by application/type for the competitive landscape analysis.
The active pharmaceutical ingredients worldwide market is in continuous development from the recent years. There is expected to be a major impact on the global API industry, with the large number of blockbuster drugs going off patent in the coming years. It is going to affect the revenue of the API market as generic drugs occupy the market.
India and China produce a large percentage of a majority of the APIs and intermediates produced in the world currently. The USFDA and EMA have strict guidelines for API manufacturing ‘Process Validation: General Principles and Practices’. While countries such as Japan and Singapore are signatories to the ICH Q7 regulation, India and China follow their national GMP guidelines. The efficiency and expertise of Asian contract manufacturers have positioned them in a very strategic space in the global pharmaceutical supply chain, with a vast majority of the APIs and intermediates being sourced from markets such as India and China.
Request a sample of Abilify-API Insights, 2017 @ http://www.orbisresearch.com/contacts/request-sample/233085 .
Abilify -API Insights, 2017 Report provides marketed details and API Manufacturers details across the globe along with the location. The report gives the clear idea on the United States Drug Master File (USDMF) and Europe DMF filed by worldwide countries related to the drug. It also provides the India and China API Manufactures who are driving the current API Market. The report also highlights the patent, patent exclusivity information and competitive landscape. The research, analysis also presents the global sales data till 2016.
The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by team of industry experts. Secondary sources information and data has been collected from various printable and non-printable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Magazines, Trade associations, Books, Industry Portals, Industry Associations and access to available databases.
Scope of the Report
A review of the Abilify based on information derived from company and industry-specific sources
Coverage of the Marketed data of the Abilify on the basis of MOA, target, dosage, route of administration, molecule type, strength, Chemical type and ATC Classification
Coverage of the United States Drug Master File (US DMF), Active Substance Master File/EU DMF and API Manufactures in China & India for drug with location details.
Patent Expiry Timeline and Exclusivity Details
Global Sales Figure from 2012-2016
Qualitative and quantitative assessment of market space Reasons to buy
Evaluate the marketing status and exclusivity details of Abilify to exploit opportunities for generic drug development opportunities.
Design effective counter-strategies to gain competitive advantage by identifying the key patent expiry details and exclusivity with respect to Abilify.
API intelligence over Abilify and gaining primary intelligence over Active Ingredients manufacturers across the globe.
Uncovering opportunities in the rapidly growing the US market
Stay ahead of competition by understanding the changing competitive landscape
Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
Make more informed business decisions from insightful and in-depth analysis of the drug’s performance
Purchase a copy of Abilify-API Insights, 2017 @ http://www.orbisresearch.com/contact/purchase/233085 .
Table of Content in this Report:
Abilify, Market, Global Sales (in USD), 2017
Abilify, Marketed Details the United States (US)
Abilify, Marketed Details the Europe (EU)
Abilify, Patent/Exclusivity Expiry (Year), 2017
Abilify, Patent Number Specific Patent Expiry (Year), 2017
Abilify, Patent Details
Abilify, the United States Drug Master File (US DMF), 2017
Abilify, the Europe Drug Master File (EUDMF)/Active Substance Master File (ASMF), 2017
Abilify, the API Manufacturers, China, 2017
Abilify, the API Manufacturers, India, 2017
Abilify, the API Manufacturers by the US DMF Status, 2017
Abilify, the API Manufacturers by Region, 2017
Abilify, the API Manufacturers by Location/Countries, 2017
Abilify, Generic Players, 2017
Company Overview, 2017
For any enquires before buying, connect with us @ email@example.com
Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.
Senior Manager – Client Engagements
4144N Central Expressway,
Suite 600, Dallas,
Texas – 75204, U.S.A.
Phone No.: +1 (214) 884-6817; +912064101019
Follow Us on LinkedIn: https://www.linkedin.com/company/orbis-research